My question is for Mr. Ferguson.
You make a point in number nine of your summary report here. You've actually cautioned us, it would appear, with regard to moving forward with a pharmacare program and making sure that we're taking into account delivery and the people, rather than looking at just the process.
I would ask you to reflect on a couple of things. First, what data is needed in order for us to move forward with a national pharmacare program from an educated standpoint, and with a delivery model that is going to be helpful rather than hindersome?
Second, what is the cost that would be associated with a pharmacare program?
Third, what would the impact be on choice be if we were to move forward with a pharmacare program?